MA29625B1 - Immunoglobulines - Google Patents
ImmunoglobulinesInfo
- Publication number
- MA29625B1 MA29625B1 MA30565A MA30565A MA29625B1 MA 29625 B1 MA29625 B1 MA 29625B1 MA 30565 A MA30565 A MA 30565A MA 30565 A MA30565 A MA 30565A MA 29625 B1 MA29625 B1 MA 29625B1
- Authority
- MA
- Morocco
- Prior art keywords
- immunoglobulin
- antibodies
- prophylaxis
- disorders
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des anticorps anti-NOGO, des formulations pharmaceutiques les contenant et l'utilisation de ces anticorps dans le traitement et/ou la prophylaxie de maladies/troubles neurologiques.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0513766A GB0513766D0 (en) | 2005-07-05 | 2005-07-05 | Immunoglobulins |
GB0525448A GB0525448D0 (en) | 2005-12-14 | 2005-12-14 | Immunoglobulins |
Publications (1)
Publication Number | Publication Date |
---|---|
MA29625B1 true MA29625B1 (fr) | 2008-07-01 |
Family
ID=37604821
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30565A MA29625B1 (fr) | 2005-07-05 | 2008-01-09 | Immunoglobulines |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP1899377B1 (fr) |
JP (1) | JP2009500363A (fr) |
KR (1) | KR20080030960A (fr) |
AU (1) | AU2006265276B2 (fr) |
BR (1) | BRPI0612734A2 (fr) |
CA (1) | CA2614076A1 (fr) |
CR (1) | CR9623A (fr) |
CY (1) | CY1113310T1 (fr) |
DK (1) | DK1899377T3 (fr) |
EA (1) | EA014291B1 (fr) |
ES (1) | ES2391902T3 (fr) |
HK (1) | HK1115598A1 (fr) |
HR (1) | HRP20120851T1 (fr) |
IL (1) | IL188282A (fr) |
MA (1) | MA29625B1 (fr) |
NO (1) | NO20076663L (fr) |
NZ (1) | NZ564567A (fr) |
PL (1) | PL1899377T3 (fr) |
PT (1) | PT1899377E (fr) |
SG (1) | SG162829A1 (fr) |
SI (1) | SI1899377T1 (fr) |
WO (1) | WO2007003421A2 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2606081C (fr) | 2005-04-26 | 2013-09-17 | Markus M. Heiss | Combinaison d'anticorps et de glucocorticoides destinee au traitement du cancer |
CN106366192B (zh) | 2007-06-25 | 2020-03-27 | 艾斯巴技术-诺华有限责任公司 | 修饰抗体的方法和具有改善的功能性质的修饰抗体 |
SI2207808T1 (sl) * | 2007-11-02 | 2013-09-30 | Novartis Ag | Izboljšane Nogo-A vezavne molekule in njihova farmacevtska uporaba |
JP2011527317A (ja) * | 2008-07-11 | 2011-10-27 | グラクソ グループ リミテッド | Nogo−aアンタゴニストによる筋萎縮性側索硬化症の治療 |
GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
HRP20220088T1 (hr) | 2018-12-21 | 2022-04-15 | Kymab Limited | Dvojno-specifično fixaxfx antitijelo sa zajedničkim lakim lancem |
GB2590642B (en) * | 2019-12-20 | 2024-02-14 | Kymab Ltd | Improved lambda antibodies |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0228832D0 (en) * | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
GB0321997D0 (en) * | 2003-09-19 | 2003-10-22 | Novartis Ag | Organic compound |
DK1711530T3 (da) * | 2003-12-22 | 2009-12-14 | Glaxo Group Ltd | Nogo-A-neutraliserende immunoglobuliner til behandling af neurologiske sygdomme |
-
2006
- 2006-07-03 BR BRPI0612734-7A patent/BRPI0612734A2/pt not_active IP Right Cessation
- 2006-07-03 NZ NZ564567A patent/NZ564567A/en not_active IP Right Cessation
- 2006-07-03 CA CA002614076A patent/CA2614076A1/fr not_active Abandoned
- 2006-07-03 PL PL06776123T patent/PL1899377T3/pl unknown
- 2006-07-03 EP EP06776123A patent/EP1899377B1/fr active Active
- 2006-07-03 PT PT06776123T patent/PT1899377E/pt unknown
- 2006-07-03 KR KR1020077031031A patent/KR20080030960A/ko not_active Application Discontinuation
- 2006-07-03 EA EA200702634A patent/EA014291B1/ru not_active IP Right Cessation
- 2006-07-03 SI SI200631454T patent/SI1899377T1/sl unknown
- 2006-07-03 WO PCT/EP2006/006535 patent/WO2007003421A2/fr active Application Filing
- 2006-07-03 JP JP2008519855A patent/JP2009500363A/ja not_active Ceased
- 2006-07-03 ES ES06776123T patent/ES2391902T3/es active Active
- 2006-07-03 SG SG201004551-6A patent/SG162829A1/en unknown
- 2006-07-03 DK DK06776123.9T patent/DK1899377T3/da active
- 2006-07-03 AU AU2006265276A patent/AU2006265276B2/en not_active Ceased
-
2007
- 2007-12-20 CR CR9623A patent/CR9623A/es not_active Application Discontinuation
- 2007-12-20 IL IL188282A patent/IL188282A/en not_active IP Right Cessation
- 2007-12-28 NO NO20076663A patent/NO20076663L/no not_active Application Discontinuation
-
2008
- 2008-01-09 MA MA30565A patent/MA29625B1/fr unknown
- 2008-05-15 HK HK08105409.6A patent/HK1115598A1/xx not_active IP Right Cessation
-
2012
- 2012-10-23 HR HRP20120851TT patent/HRP20120851T1/hr unknown
- 2012-11-05 CY CY20121101051T patent/CY1113310T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
NO20076663L (no) | 2008-02-27 |
CA2614076A1 (fr) | 2007-01-11 |
AU2006265276A1 (en) | 2007-01-11 |
SI1899377T1 (sl) | 2012-12-31 |
HRP20120851T1 (hr) | 2012-11-30 |
KR20080030960A (ko) | 2008-04-07 |
HK1115598A1 (en) | 2008-12-05 |
EP1899377B1 (fr) | 2012-08-22 |
EP1899377A2 (fr) | 2008-03-19 |
WO2007003421A2 (fr) | 2007-01-11 |
NZ564567A (en) | 2010-09-30 |
ES2391902T3 (es) | 2012-11-30 |
DK1899377T3 (da) | 2012-11-12 |
CY1113310T1 (el) | 2016-04-13 |
JP2009500363A (ja) | 2009-01-08 |
EA200702634A1 (ru) | 2008-06-30 |
CR9623A (es) | 2008-04-10 |
AU2006265276B2 (en) | 2011-10-13 |
SG162829A1 (en) | 2010-07-29 |
WO2007003421A3 (fr) | 2007-04-12 |
PT1899377E (pt) | 2012-11-20 |
IL188282A (en) | 2011-04-28 |
BRPI0612734A2 (pt) | 2010-11-30 |
IL188282A0 (en) | 2008-04-13 |
EA014291B1 (ru) | 2010-10-29 |
PL1899377T3 (pl) | 2013-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30041B1 (fr) | Immunoglobulines | |
MA28289A1 (fr) | Immunoglobulines | |
MA29625B1 (fr) | Immunoglobulines | |
MA30340B1 (fr) | Nouveaux composes | |
MA30962B1 (fr) | Anticorps antifacteurs d'humanisés et leurs utilisations. | |
MA32804B1 (fr) | Antagonistes d'isonicotinamide des récepteurs de l'orexine | |
TNSN04268A1 (fr) | UTILISATION D'INHIBITEURS CETP ET FACULTATIVEMENT D'INHIBITEURS DE HMG -CoA - REDUCTASE ET/OU D'AGENTS ANTI-HYPERTENSIFS | |
MA33381B1 (fr) | Proteine de liaison a il-13 | |
MA30462B1 (fr) | Composes de pyridylamide antagonistes des canaux calciques de type t | |
TNSN97192A1 (fr) | Derives de pyrimidine bicycliques condenses, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
MA27675A1 (fr) | Derives de piperazine et leur utilisation dans le traitement de maladies neurologiques et psychiatriques | |
BR0214705A (pt) | Composição, seu uso, método para prevenção ou tratamento de doença neurodegenerativa, e kit | |
MA32226B1 (fr) | Compositions et leurs procedes de preparation et d'utilisation | |
TNSN07063A1 (fr) | Utilisations therapeutiques d'inhibiteurs de rtp801 | |
MA34655B1 (fr) | Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse | |
MEP42808A (en) | Use of flibanserin in the treatment of sexual disorders | |
ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
MA27334A1 (fr) | Utilisation d'inhibiteurs de l'ikb kinase dans le traitement de la douleur | |
MA29169B1 (fr) | Formulations intraveineuses d'inhibiteurs de la pde-5 | |
ATE409176T1 (de) | 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen | |
MA30539B1 (fr) | Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38. | |
MA33753B1 (fr) | Nouveaux camphènes arylés, procédés de préparation et utilisations de ceux-ci | |
ATE355288T1 (de) | Verbindungen und therapeutische methoden | |
TR200002626T2 (tr) | Terkip | |
DE60326069D1 (de) | 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen |